The Epigenomics Core contributes a critical and significant role to the overall PO1 program goal of identifying and characterizing novel therapeutic vulnerabilities in breast cancer. The research projects making up the program have research strategies that utilize genome-wide analysis of cancer cell epigenomes at both the bulk and single cell level. Additionally, several propose the use of screens involving genome editing. The primary objective of the Epigenomics Core is to support the PO1 Projects with expertise in epigenomic profiling and CRISPR screens. This includes the Program with both the key experimental and computational capabilities required to meet these essential programmatic needs. The Core is directed by Dr. Henry W. Long, an experienced, highly productive laboratory scientist based at the Center for Functional Cancer Epigenetics (CFCE) at the Dana-Farber Cancer Institute in Boston. Dr. Long has a history of innovation in providing the critical resources and services to research projects in breast and other cancers over the past 9 years at the CFCE. Dr. Long has a very strong track record of innovation in epigenetics applied to cancer biology. The Core?s mission is to provide state-of-the-art services to the projects in an efficient, cost-effective, and quality- focused manner and the specific aims are designed to provide resources in epigenetics and CRISPR screens.
